NCT01174030

Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

A 4-week, Randomized, Double-blind, Parallel-group, Vehicle-controlled, Multicenter Study Investigating the Efficacy and Safety of CD07805/47 Gel 0.5% Applied Topically Once Daily (QD), and CD07805/47 Gel 0.18% Applied Topically Once Daily (QD) or Twice Daily (BID), in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 269 (actual)
• Sponsor: Galderma R&D · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this vehicle controlled study is to evaluate the efficacy and safety of CD07805/47 gel 0.5% applied topically once daily (QD) for 4 weeks, and CD07805/47 gel 0.18% applied topically once daily (QD) or twice daily (BID) for 4 weeks, in subjects with moderate to severe facial erythema associated with rosacea.

Conditions

• Rosacea

Interventions

Type	Name	Description
DRUG	CD07805/47 Gel	CD07805/47 Gel 0.5% QD
DRUG	Vehicle Gel	Vehicle Gel QD
DRUG	CD07805/47 Gel	CD07805/47 Gel 0.18% QD
DRUG	CD07805/47 Gel	CD07805/47 Gel 0.18% BID
DRUG	Vehicle Gel	Vehicle Gel BID

Timeline

• Start date: 2010-08-01
• Primary completion: 2010-12-01
• Completion: 2011-01-01
• First posted: 2010-08-03
• Last updated: 2021-02-26
• Results posted: 2014-03-11

Locations

20 sites across 1 country: United States